Molecular dynamics simulation and docking studies reveal NF-κB as a promising therapeutic drug target for COVID-19

Shaban Ahmad
International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi-110 067, India; Department of Computer Science, Jamia Millia Islamia, New Delhi-110025, India

Piyush Bhanu
Xome Life Sciences, Bangalore Bioinnovation Centre, Helix Biotech Park, Bengaluru, Karnataka – 560100. India

Jitendra Kumar
Bangalore Bioinnovation Centre (BBC), Helix Biotech Park, Electronics City Phase 1, Bengaluru, Karnataka – 560100. India

Ravi Kant Pathak
School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar - Delhi, Grand Trunk Rd, Phagwara, Punjab 144001. India

Dharmendra Mallick
Department of Botany, Deshbandhu College, University of Delhi, Delhi – 110019. India

Akshay Uttarkar
Department of Biotechnology, RV College of Engineering, RV Vidyanikethan Post, Mysuru Road, Bengaluru 560059

Vidya Niranjan
Department of Biotechnology, RV College of Engineering, RV Vidyanikethan Post, Mysuru Road, Bengaluru 560059

Vachaspati Mishra (✉️ mishravachaspati31@gmail.com)
Department of Botany, Dyal Singh College, University of Delhi, New Delhi 110003
https://orcid.org/0000-0002-5802-9821

Research Article

Keywords: NF-κB, Molecular dynamics simulation, COVID-19, SARS-CoV, Sulindac sodium

DOI: https://doi.org/10.21203/rs.3.rs-469785/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rampant worldwide and is a deadly disease for humans. Our current work emphasizes on molecular dynamics simulation (MDS) targeting nuclear factor-kappa B (NF-κB), the well-known human transcription factor controlling innate and adaptive immunity, to understand its mechanism of action during COVID-19 in humans. NF-κB was interacted with the SARS-CoV-2 spike protein in an in silico MDS experiment, revealing the NF-κB site at which the SARS-CoV-2 spike protein interacts. We screened some known drugs via docking studies on NF-κB used as a receptor. The MDS software Schrodinger generated more than 2000 complexes from these compounds and using the SMILES format of these complexes, 243 structures were extracted and 411 conformers were generated. The drug used as a ligand that docked with NF-κB with the best docking score and binding affinity was Sulindac sodium as its trade name. Furthermore, RMSF data of sulindac sodium and NF-κB displayed minimal fluctuations in the protein structures, and the protein-ligand complex had reduced flexibility. Sulindac sodium is hence suggested as a suitable drug candidate for repurposing in clinical trials for SARS-CoV-2 infections. This drug potently blocked the spike protein's interaction with NF-κB by inducing a conformational change in the latter. Arguably, NF-κB inaction is desired to have normal immunity and can possibly be retained using proposed drug. This work provides a significant lead for drug repurposing to combat SARS-CoV-2 and its various mutant forms and reveals new approach for controlling SARS-CoV-2-induced disease.

Introduction

In a normal state of physiological activity, our immune system maintains homeostasis in the expression levels of NF-kappa B (NF-κB), which remains in a steady state by staying in a complex of proteins (such as IκBs), not allowing NF-κB to dissociate and translocate to the nucleus from the cytosol to exert its activity. However, stimuli trigger the activation of NF-κB through phosphorylation of IκBs by IκB kinase (IKK), which leads to nuclear translocation of NF-κB, where it binds to its cognate DNA and activates transcription of a wide variety of genes involved in host immunity, inflammation, cell proliferation and apoptosis (Oeckinghaus and Ghosh 2009). Various NF-κB inducers are known to be highly variable and include aggregates of bacterial lipopolysaccharides, ionizing radiation, reactive oxygen species (ROS), cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin 1-beta (IL-1β) and viral DNA and RNA (Zhang et al. 2017). Upon activation, NF-κB promotes the gene expression of a broad range of cytokines (e.g., IL-1, IL-2, IL-6, IL-12, TNF-α, LT-α, LT-β, and GM-CSF), chemokines (e.g., IL-8, MIP-1, MCP1, RANTES, and eotaxin), adhesion molecules (e.g., ICAM, VCAM, and E-selectin), acute phase proteins (e.g., serum amyloid A: SAA), and inducible effector enzymes (e.g., inducible nitric oxide synthase: iNOS and cyclooxygenase-2: COX-2). NF-κB can be considered a “quick action” primary transcription factor that is able to regulate myriad cellular responses, including the host’s early innate immune response to infection, and is also associated with chronic inflammatory states, viral infections, septic shock syndrome and multiorgan failure (Zhang et al. 2017; Li and Verma 2002). The constitutive activation of NF-κB pathways
has been found to be stimulated during inflammatory diseases, such as multiple sclerosis and rheumatoid arthritis (Liu et al. 2017).

Since coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and became a pandemic worldwide, research on immediately available drugs that can block the causative virus or boost the human immune system to counter this virus has become rampant. With a lack of adequate specific treatment for COVID-19, there is urgency to develop or repurpose drugs to help end the epidemic soon. The World Health Organization launched trials to investigate four potential treatments: remdesivir; chloroquine/hydroxychloroquine; lopinavir and ritonavir; and lopinavir and ritonavir plus interferon-β.1 (Neufeldt et al., 2020). However, these kinds of trials need to include thousands of patients from several countries and hence will consume a large amount of time and money. Furthermore, countries have developed their own vaccines, but proving their worth still requires further monitoring. We therefore need to urgently develop more focused therapy before the virus begins killing humans in an exponential manner.

The drug discovery process has received a great impetus with the emergence of computer-aided drug discovery (CADD) and has been instrumental over the last decade in exploring protein inhibitors in protein-drug interactions and protein–protein interactions (Keretsu et al., 2020). Since the process involved in the development of a candidate drug into an approved drug is lengthy and expensive, a combination of computational methodologies such as virtual screening, docking, molecular dynamics simulation (MDS), and binding free energy evaluation contributes to identifying potential drug candidates from compound libraries (Elmezayen et al., 2020). To date, MDS and structure-based virtual screening studies have been carried out to understand the SARS-CoV-2 spike protein function (Arantes et al., 2020; Selvaraj et al., 2020), role of repurposed protease inhibitors in blocking SARS-CoV-2 (Cardoso and Mendanha, 2021), effects of some antiviral drugs on SARS-CoV-2 (Zhao et al., 2020), and effect of temperature on the structure of the spike protein (Lipsa Rath and Kumar, 2020) and to perform molecular docking and simulation studies on SARS-CoV-2 elucidating some potent drugs that can be effective in controlling COVID-19 (Lokhande et al., 2020), as well as many other aspects of SARS-CoV-2 biology. However, the rate of occurrence of different pathological human phenotypes and their heterogeneous lethality rates arising from constant mutations of SARS-CoV-2 (Martinez et al., 2020)) indicate serious problems that need to be appropriately addressed. A recent study revealed the importance of the NF-κB pathway in developing therapy regimens for critical COVID-19 patients (Hariharan et al., 2021). Other reports have also substantiated the above fact by arguing that therapeutic benefits of NF-κB inhibitors, including dexamethasone, a synthetic form of glucocorticoid, have increasingly been realized (Elkhodary, 2020). Abnormal activation of NF-κB resulting from SARS-CoV-2 infection might be associated with the pathogenic profile of immune cells, cytokine storms and multiorgan defects (Elkhodary, 2020).

Motivated by the mentioned facts, we currently explored the structural details of NF-κB via an in silico approach wherein we pinpointed the protein pockets for the binding of SARS-CoV-2 spike proteins. While performing its function upon entering the human body, this viral protein may trigger the action of the NF-κB transcription factor directly or may activate IKK, the kinase phosphorylating IκBs that otherwise
remain bound with NF-κB to keep it inactive and in the cytoplasm. IκBα is known to be phosphorylated by specific kinases at two sites near the N-terminus (Ser-32 and Ser-36), while the phosphorylated protein is then ubiquitinated at Lys-21 and Lys-22, leading to proteosome-mediated degradation (Wang et al., 2020). Removal of IκB unmasks the nuclear localization sequence (NLS) of NF-κB and allows its translocation to the nucleus. Thus, IκBα is a multifunctional inhibitor of NF-κB that blocks nuclear translocation, DNA binding, and phosphorylation by PKA. Inhibition of NF-κB inhibits the NF-κB-mediated deactivation of immune and inflammatory responses to stimuli such as cytokines or bacterial/viral infection products (Wang et al., 2020). We further report here the NF-κB amino acids that interact with the viral spike protein to show the precise protein pocket location on NF-κB (Fig. 4B). Concomitantly, our selected drug named sulindac sodium (molecular formula: C20H16FO3S) from a total of 411 conformers was generated using the ligand preparation wizard and docked at the active site (used site map for identification) using Glide. The drug currently chosen has a prior history of use as therapy in various human diseases (Brunell et al., 2011; Marchetti et al., 2009) and was currently subjected to MDS together with the SARS-CoV-2 spike protein and NF-κB separately (Fig. 1.). Interestingly, our molecular dynamics simulation data revealed some interesting features. Sulindac sodium was able to block the interaction between the spike protein and NF-κB at its designated pocket, where the former normally interacts with NF-κB and leads the spike protein to interact at another (possibly non-specific) site on NF-κB. This could possibly keep NF-κB inactive in the cytoplasm. An MDS study on the NF-κB pocket showed the presence of most of the residues (Fig. 4C) that interact with the spike protein; thus, drug binding to the NF-κB-spike protein complex interferes with the interaction of the spike protein complex. In the presence of the drug molecule, the spike protein binds to the NF-κB-IκB complex using a pocket other than that used when it binds in the absence of the drug molecule. Furthermore, our analysis revealed that in the presence of the drug molecule, the spike protein failed to interact with IκB.

We further investigated the changes in the 3-D structure of the NF-κB-IκB complex due to the binding of the drug molecule and the binding of the spike protein in the presence of the drug molecule compared to the unbound complex. It was found that due to binding of the drug molecule, the compactness of the complex increased. The compactness further increased due to the binding of the spike protein in the presence of the drug molecule. The increase in compactness can be understood as an increase in the interaction between the chains of the NF-κB-IκB complex, which further supports the finding that in the presence of the drug molecule, the inactivity of NF-κB is further enhanced. We also employed MM-GBSA (molecular mechanics energies combined with the Poisson–Boltzmann or generalized Born and surface area continuum solvation) to estimate ligand binding affinities for sodium sulindac and receptor NF-κB and the values found as -2.15 kcal/mol for MMGBSA dG bind and -2.71 kcal/mol for MMGBSA dG bind(NS) show strong interaction between the two.

Materials And Methods

A. Protein and Ligand Preparation
Coordinates of the X-ray diffraction-based crystal structure of the I-κ-B-α/NF-κB complex with solvents (PDB ID: 1NFI) at a resolution of 2.70 Å were downloaded from the Protein Data Bank (PDB). The PDB IDs of the structures used were recorded. Solvent molecules and chains A, B, and F were removed during protein preparation (Fig. 4A). using the Protein Preparation wizard from Schrodinger Maestro (Schrödinger, LLC, New York, NY). The remaining structures were first preprocessed using the Protein Preparation wizard, which included proper assignment of bond order; adjustment of ionization states; orientation of disoriented groups; creation of disulfide bonds; removal of unwanted water molecules, metal and cofactors; capping of the termini; assignment of partial charges; and addition of missing atoms and side chains. In the case of the SARS-CoV structure, a loop (residues 376–381) missing in the PDB structure was modelled using Schrödinger’s Prime module. Hydrogen atoms were incorporated, and a standard protonation state at pH 7 was used. Bond orders were assigned using the chemical components dictionary (CCD) database. The heterostate was generated using Epik with a pH of 7 (+/-2.0), and Prime was used to fill the missing chains and loops. Furthermore, all water molecules were removed in updated structures. While refining the structure, PROPKA with pH 7.0 was used along with the sample water orientation. While minimizing the structure, a root mean square deviation (RMSD) of 0.30 Å with the OPLS_2005 force field was used. The ligand was selected based on published information regarding its use as a therapeutic molecule for various human diseases and its efficiency in yielding positive results with AutoDock- and Swiss Dock-based docking with NF-κB (Kumar et al., 2021, unpublished data). The ligand was prepared using the Ligprep wizard of Schrodinger with the OPLS_2005 force field; the Epik job was submitted with the metal-binding site and included the original state. Thirty-two stereoisomers were assigned per ligand with specified chirality. Glide was used to filter the search to locate the ligand in the active-site region of the receptor. The shape and properties of the receptor were represented on a grid to provide a more accurate scoring of the ligand poses. The docked complexes were superimposed on the original crystal structure to calculate the RMSD.

B. Virtual Screening and Molecular Docking

The Glide grid generator was used for generating the grid for blind docking. A Schrodinger virtual screening workflow (VSW) was used to score the virtual screening with default parameters employing the Glide program of Schrödinger. Use of HTVS mode allowed the elimination of most of the stereoisomers, and only 10% of the total ligands could be retained that passed the screening. Ligands following QikProp and Lipinski’s rule were filtered for docking. Docking in the VSW was performed with Epik state penalties and further passed through HTVS, SP and XP docking modes. The ligands that showed the best affinity towards the main protease qualified for our study. Finally, the interactions of the selected ligand and protein docked complexes were analysed by a poseviewer.

C. Molecular Dynamics Simulation

To study the dynamic behaviour of the protein complex under simulated physiological conditions, MDSs of the protein-ligand (PL) complex were performed using Desmond, which is available with Schrodinger Maestro (v12.5). The PL complex (9873 atoms) was solvated in a 10 × 10 × 10 Å orthorhombic periodic
box built with TIP3P water molecules (Jorgensen, Chandrasekhar, Madura, Impey, & Klein, 1983). The whole system was neutralized by adding an appropriate number of 6 Na\textsuperscript{+} counterions. This solvated system was energy minimized and position restrained with OPLS_2005 as the force field (Jorgensen and Tirado-Rives 1988). Furthermore, 100 ns of MDS was carried out at 1 atm pressure and 300 K temperature, implementing the NPT ensemble with a recording interval of 100 ps, resulting in a total of 1000 read frames. Finally, various parameters of the MDS, such as ligand-binding site analysis, RMSD, root mean square fluctuation (RMSF), PL contacts, secondary structure element (SSE) analysis, etc., were also analysed to check the stability, compactness, structural fluctuations and PL interactions in the solvated system.

### D. Interaction Analyses

1. Structural Data:

The PDB was used to extract all 3-D structural information. The X-ray diffraction-based crystal structure of the I-κ-B-α/NF-κB complex with solvents (PDB ID: 1NFI) at a resolution of 2.70 Å was used for this study. Solvents and chains A, B, and F were removed during protein preparation (Fig. 4A). The structure of the SARS-CoV-2 spike glycoprotein (closed state) solved using electron microscopy (PDB ID: 6VXX) with a resolution of 2.80 Å was obtained (Fig. 4B.). Furthermore, all water molecules were removed from both structural data sets. The educational version of PyMOL (The PyMOL Molecular Graphics System, v1.2r3pre, Schrödinger, LLC) was used to generate the images derived to understand and analyse the structure and interchain interaction information.

2. Pocket Analysis:

NF-κB has multiple pockets, as calculated using the CASTp 3.0 server (Liang et al., 2018). Out of these pockets, the three largest pockets (based on the accessible area) were considered for analysis. The residues present in these pockets were considered interacting residues (Fig. 4). The area of the pockets and the interacting residues (exposed) changed significantly due to interaction with the spike protein and the drug molecule or the combination of the two.

3. Molecular Docking:

The Schrodinger VSW was used for virtual screening with default parameters using the Glide program. HTVS mode eliminated most of the stereoisomers, and only a few of the isomers passed after screening. QikProp and Lipinski’s rule were further used to select the ligands without the functional group that were screened beforehand. Ligands were already prepared using the Ligprep wizard of Schrodinger with the OPLS_2005 force field. Less than or equal to 32 stereoisomers were assigned per ligand with specified chirality. Docking in the VSW was performed with Epik state penalties and further passed through HTVS, SP and XP docking modes. The ligands that showed the best affinity towards the main protease qualified. Finally, we found 1 unique ligand that showed the best docking score and binding affinity (Fig.
3). The complex of the drug molecule docked in the pocket of NF-κB was designated S0 (Fig. 4A) and was taken as the reference for further interaction comparative analysis.

4. Protein-Protein Docking:

Protein-protein docking studies were carried out using ClusPro 2.0 (Vajda et al., 2017) to understand the interaction of the SARS-CoV-2 spike glycoprotein with NF-κB in the presence and absence of the drug molecule. The best pose of the spike protein binding with the NF-κB-IκB complex was selected based on the cluster size, which is how the models are ranked in ClusPro. S1 (Fig. 4B) represents the complex of NF-κB with the SARS-CoV-2 spike glycoprotein, and S2 (Fig. 4C) represents the complex of S0 with the SARS-CoV-2 spike glycoprotein.

5. Interaction Studies

LigPlot+ v.2.2 (Laskowski and Swindells, 2011) was used to find the ligand-protein interaction of complex S0 (Fig. 2). PDBsum was used to calculate the interaction between NF-κB and IκB (Fig. 5B), the interaction between the spike protein and NF-κB (Fig. 5B) and the interaction between the spike protein and NF-κB docked with drug molecules. PyMOL was used to analyse the structural differences imposed on NF-κB when it interacted with the drug molecule and the spike protein in the presence of the drug molecule.

6. MM-GBSA Studies

Prime MM-GBSA (molecular mechanics, the generalized Born model and solvent accessibility method) calculations were performed with the docked complex of receptor and Sulindac. The implicit solvent model used is VSGB (Li et al., 2011) which has an efficient approximation of the solvation free energy with Surface Generalized Born (SGB) over Vacuum and chloroform solvation models. The following calculations were made

1. Rec Strain = Receptor (from optimized complex) – Receptor
2. Lig Strain = Ligand (from optimized complex) – Ligand
3. MMGBSA dG Bind = Complex – Receptor – Ligand
4. MMGBSA dG Bind(NS) = Complex – Receptor(from optimized complex) – Ligand(from optimized complex) = MMGBSA dG Bind – Rec Strain – Lig Strain

NS here refers to binding or interaction energy without any involvement of conformational changes occurring in the receptor or ligand. The potential energy of the complex will be reported in kcal/mol.

Results And Discussion

1. MD Simulation Studies
MDSs of the PL complex were carried out using Desmond 6.1 (Maestro v12.5), which provides information about the receptor-ligand complex over time. Thus, we performed MDSs for 100 ns on the complex after docking. After the simulation, we analysed the trajectory files for RMSD, RMSF, PL interactions, etc.

2. Root Mean Square Deviation (RMSD)

The RMSD is an indicator that describes the average displacement of an atom in a specific molecular conformation concerning a reference conformation. In trajectory analysis, the complex RMSD in the initial phase at 1.63 Å went to 4.11 Å while stabilizing the structure for 100 ns of simulation. Initially, at up to 50 ns, the RMSD did not fluctuate much, but after that, the stability fluctuated for 10 ns and again started stabilizing. The c-α RMSD fluctuated initially up to 1.47, after which a small fluctuation was noticed (Fig. 1). Local changes along the protein chain were calculated throughout the simulation deliberations, and the RMSF was studied to characterize such changes. The RMSD of each residue of a conformation in a frame relative to the average conformation was studied to determine the flexibility of a region of the protein. The peak in the RMSF plot indicated the protein's maximum fluctuation during the simulation work, and the lower RMSF values represent fewer conformational changes. Overall, the RMSF plot analysis displayed minimal fluctuations in the protein structures (Fig. 2). Furthermore, minimal fluctuations were also observed in the PL complex, and the RMSF plot showed fluctuations in some regions of the protein. The results of the residue interaction analysis after docking are highlighted with specific colours based on the features (Fig. 3).

We assumed that the spike protein of SARS-CoV-2 directly interacts with IkB and dislocates this molecule from the IkB and NF-κB complex. However, this hypothesis was not found to be true based on the docking outcomes of the spike protein and NFκB (Fig. 4A). We further identified the ligand that could strengthen the interaction between IkB and NF-κB so that the spike protein of SARS-CoV-2 could not activate NF-κB for nuclear translocation, remaining in the inactive form in the cytoplasm, as shown in Fig. 4C. We studied the docking interactions of the identified drug and found that it docked in the largest pocket of the NF-κB-IkB complex that contains most of the residues interacting with the spike protein. It is possible that drug binding to the complex interferes with the above interaction of the spike protein. In the presence of the drug molecule, the spike protein bound to the NF-κB-IkB complex using a pocket other than that used when it binds in the absence of the drug molecule (Fig. 4C). Additionally, the drug molecule did not allow the spike protein to interact with IkB.

The changes in the 3-D structure of the NF-κB-IkB complex due to the binding of the drug molecule and spike protein in the presence of the drug molecule were compared to that of the unbound complex (Fig. 5A). The binding of the drug molecule to the NF-κB-IkB complex led to an increase in the compactness of the complex. The area and volume data regarding the pockets presented in Fig. 5A corroborated this observation. The binding of the spike protein in the presence of the drug molecule further increased the compactness of this complex. The increase in compactness can be understood as the increase in the
interaction between the chains of the NF-κB-IκB complex, which further supports the finding that in the presence of the drug molecule, the inactivity of NF-κB is enhanced.

MM-GBSA studies are performed for docked complexes to accurately measure relative binding energy/affinity. MMGBSA dG bind values have a reasonable agreement with ranking based experimental scores, i.e., binding values (Uttarkar and Niranjan, 2021). Higher negative values refer to stronger binding. In the current study, we calculated first the MMGBSA dG Bind = Prime Energy (Optimized Complex) – Prime Energy (Optimized Free Ligand) – Prime Energy (Optimized Free Receptor) and second, MMGBSA dG Bind(NS) = Prime Energy (Optimized Complex) – Prime Energy (Ligand Geometry From Optimized Complex) - Prime Energy (Receptor Geometry From Optimized Complex). The values were found to be -2.15 kcal/mol for MMGBSA dG bind and -2.71 kcal/mol for MMGBSA dG bind(NS). The atoms contributing to the binding affinities can be found in Fig. 7.

At present, our understanding of the involvement of the NF-κB signalling pathway in COVID-19 is limited, but NF-κB inhibitors have been increasingly utilized to gain therapeutic benefits in many human diseases (Park and Hong, 2016; Yu et al., 2020). Abnormal activation of NF-κB in the manifestation of SARS-CoV-2 infection is considered associated with the pathogenic profile of immune cells, cytokine storms and multiorgan defects. Thus, pharmacological inactivation of the NF-κB, such as proposed currently in the use of sulindac sodium, NF-κB-kinase interaction either directly or by inhibiting the dephosphorylation of its inhibitors, such as IKKα, IKKβ and other associated molecules, strongly represents a potential therapeutic target to treat the symptoms of COVID-19 in clinical trials.

Declarations

Acknowledgements

The authors acknowledge the International Centre for Genetic Engineering and Biotechnology, New Delhi, for providing facilities for MDS studies.

Competing Interest Statement

The authors declare that there are no conflicts of interest.

References

Beg A.A., Ruben S.M., Scheinman R.I., Haskill S., Rosen C.A., Baldwin Jr., A. IκB interacts with the nuclear localization sequences of the subunits of NF-κB a mechanism for cytoplasmic retention. Genes Dev. 1992; 6: 1899-1913.

Brunell D, Sagher D, Kesaraju S, Brot N, Weissbach H. Studies on the metabolism and biological activity of the epimers of sulindac. Drug Metab Dispos. 2011 Jun;39(6):1014-21. doi: 10.1124/dmd.110.037663. Epub 2011 Mar 7. PMID: 21383205; PMCID: PMC3100905.
Cardoso WB, Mendanha SA. Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors. J Mol Struct. 2021 Feb 5;1225:129143. doi: 10.1016/j.molstruc.2020.129143. Zhao et al., 2020

Christopher J. Neufeldt, Berati Cerikan, Mirko Cortese, Jamie Frankish, Ji-Young Lee, Agnieszka Plociennikowska, Florian Heigwer, Sebastian Joecks, Sandy S. Burkart, David Y. Zander, Mathieu Gendarme, Bachir El Debs, Niels Halama, Uta Merle, Michael Boutros, Marco Binder, Ralf Bartenschlager bioRxiv 2020.07.21.212639; doi: https://doi.org/10.1101/2020.07.21.212639.

Elkhodary, M. (2020). Treatment of COVID-19 by controlling the activity of the nuclear factor-Kappa B. CellBio, 09, 109–121.

Elmezayen, A. D., Al-Obaidi, A., Şahin, A. T. & Yelekçi, K. Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J. Biomol. Struct. Dyn. https://doi.org/10.1080/07391102.2020.1758791 (2020).

Ganchi P.A., Sun S.C., Greene W.C., Ballard D.W. IκB/MAD-3 masks the nuclear localization signal of NF-κB p65 and requires the transactivation domain to inhibit NF-κB p65 DNA binding. Mol. Biol. Cell. 1992; 3: 1339-1352.

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O'Neal MC, Cai Y, Chang JC, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9.

Hariharan, A., Hakeem, A.R., Radhakrishnan, S. et al. The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients. Inflammopharmacol 29, 91–100 (2021). https://doi.org/10.1007/s10787-020-00773-9.

Jacobs MD, Harrison SC. Structure of an IκBalpha/NF-κB complex. Cell. 1998 Dec 11;95(6):749-58. doi: 10.1016/s0092-8674(00)81698-0. PMID: 9865693.
Jorgensen, W.L.; Tirado-Rives, J., "The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin," J. Am. Chem. Soc., 1988, 110(6), 1657-1666.

Kandasamy M. (2021). NF-κB signalling as a pharmacological target in COVID-19: potential roles for IKKβ inhibitors. Naunyn-Schmiedeberg's archives of pharmacology, 394(3), 561–567. https://doi.org/10.1007/s00210-020-02035-5.

Keretsu, S., Bhujbal, S.P. & Cho, S.J. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation. Sci Rep 10, 17716 (2020). https://doi.org/10.1038/s41598-020-74468-0.

Kozakov D, Hall DR, Xia B, Porter KA, Padhony D, Yueh C, Beglov D, Vajda S. The ClusPro web server for protein-protein docking. Nat Protoc. 2017 Feb;12(2):255-278. doi: 10.1038/nprot.2016.169. Epub 2017 Jan 12. PMID: 28079879; PMCID: PMC5540229.

Kumar, J., Bhanu, P., Buchke, S., Kumar, NH., Mallick, D. and Mishra, V. 2021. Screening of potential viral drugs for COVID-19 by targeting the nuclear factor-kappa B receptor. (Unpublished)

Laskowski R A, Jabłonśka J, Pravda L, Vařeková R S, Thornton J M (2018). PDBsum: Structural summaries of PDB entries. Prot. Sci., 27, 129-134.

Laskowski R A, Swindells M B (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model., 51, 2778-2786. PMID: 21919503

Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002 Oct;2(10):725-34. doi: 10.1038/nri910.

Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023–. doi: 10.1038/sigtrans.2017.23.

Lokhande KB, Doiphode S, Vyas R, Swamy KV. Molecular docking and simulation studies on SARS-CoV-2 Mpro reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19. J Biomol Struct Dyn. 2020 Aug 20:1-12. doi: 10.1080/07391102.2020.1805019. Epub ahead of print. PMID: 32815481; PMCID: PMC7484567.

Mahase E. Covid-19: what treatments are being investigated? BMJ 2020; 368 :m1252 doi:10.1136/bmj.m1252.

Marchetti M, Resnick L, Gamliel E, Kesaraju S, Weissbach H, et al. (2009) Sulindac Enhances the Killing of Cancer Cells Exposed to Oxidative Stress. PLOS ONE 4(6): e5804. https://doi.org/10.1371/journal.pone.0005804.
Martinez IL, Llinás DT, Romero MB, Salazar LM (2020) High Mutation Rate in SARS-CoV-2: Will It Hit Us the Same Way Forever?. J Infect Dis Epidemiol 6:176. doi.org/10.23937/2474-3658/1510176.

Murugan NA, Kumar S, Jeyakanthan J, Srivastava V. Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach. Sci Rep. 2020 Nov 5;10(1):19125. doi: 10.1038/s41598-020-75762-7.

Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034. doi: 10.1101/cshperspect.a000034.

Pablo R. Arantes, Aakash Saha, and Giulia Palermo. Fighting COVID-19 Using Molecular Dynamics Simulations. ACS Central Science 2020 6 (10), 1654-1656.DOI: 10.1021/acscentsci.0c01236.

Park MH, Hong JT. Roles of NF-kB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches. Cells. 2016 Mar 29;5(2):15. doi: 10.3390/cells5020015. PMID: 27043634; PMCID: PMC4931664.

Rath SL and Kumar K (2020) Investigation of the Effect of Temperature on the Structure of SARS-CoV-2 Spike Protein by Molecular Dynamics Simulations. Front. Mol. Biosci. 7:583523. doi: 10.3389/fmolb.2020.583523

Li, J.; Abel, R.; Zhu, K.; Cao, Y.; Zhao, S.; Friesner, R. A., "The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling," Proteins, 2011, 79, 2794-812

Akshay Uttarkar and Vidya Niranjan, "Re-profilng of natural inhibitor via combinatorial drug screening: Brefeldin A variant design as an effective antagonist leading to EPAC2 structure modification and antibody design for identification", BioRxiv, 2021

Selvaraj C, Dinesh DC, Panwar U, Abhirami R, BOURA E, Singh SK. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19. J Biomol Struct Dyn. 2020 Jun 22:1-12. doi: 10.1080/07391102.2020.1778535. Epub ahead of print. PMID: 32567979; PMCID: PMC7332868.

Tian W, Chen C, Lei X, Zhao J, Liang J. CASTp 3.0: computed atlas of surface topography of proteins. Nucleic Acids Res. 2018 Jul 24;46(W1):W363-W367. doi: 10.1093/nar/gky473. PMID: 29860391; PMCID: PMC6031066.

Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Brabergh H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, UGur FS, Koh C, Savar NS, Tran QD, Shengjuler D,
Fletcher SJ, O’Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d’Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9.

Wang Q.; Zhang Y.; Wu L.; Niu S.; Song C.; Zhang Z.; Lu G.; Qiao C.; Hu Y.; Yuen K.-Y.; et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020, 181, 894–904.e9. 10.1016/j.cell.2020.03.045.

Wang X, Peng H, Huang Y, Kong W, Cui Q, Du J, Jin H. Post-translational Modifications of IκBα: The State of the Art. Front Cell Dev Biol. 2020 Nov 5;8:574706. doi: 10.3389/fcell.2020.574706. PMID: 33224945; PMCID: PMC7674170.

Yu, H., Lin, L., Zhang, Z. et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Sig Transduct Target Ther 5, 209 (2020). https://doi.org/10.1038/s41392-020-00312-6

Zhang et al. 2017; Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell. 2017 Jan 12;168(1-2):37-57. doi: 10.1016/j.cell.2016.12.012.

**Figures**
Figure 1

Root mean square deviation (RMSD) of the protein and ligand after the initial RMSD values were stabilized. This plot shows RMSD values for the protein on the left Y-axis, whereas for the ligand, these values are indicated on the right Y-axis. The RMSD graph for c-αis shown in blue colour, and for ligand fit on the protein, it is in red colour.
Figure 2

RMSF of the protein backbone and ligand complex. Red colour shows the B factor means of the PDB structure, and green colour indicates the interaction of the ligand with the protein.

Figure 3
Fig. 3A. Diagram showing detailed ligand atom interactions with the protein residues. Interactions that occur more than 7.0% of the simulation time in the selected trajectory from 0.00 through 100.00 ns. The highlighted structure represents the ligand (drug) molecule. The interacting residues are shown in circular shapes with the representation of chains as C (representing residues of the NFκB molecule) and E (representing residues of IkBα). Circles with H2O represent the water-mediated H-bond interactions. Fig. 3B. A timeline representation of the interactions and contacts (H-bond, hydrophobic, ionic, and water bridge) summarized in the above figure. The top panel shows the total number of specific contacts that the protein makes with the ligand over the course of the trajectory. The bottom panel shows specific residues interacting with the ligand in each trajectory frame. Some residues make more than one specific contact with the ligand, which is represented by a darker shade of orange according to the scale shown to the right of the plot. The interaction made by the drug molecule with the residues of the active site cavity of NF-kB, IkB and P50 peptide chains is dynamic in nature and formed, broke and reformed during the simulation duration (Fig. 3C). A brief duration of 20 ns was observed when no interaction occurred between the drug molecule and the NF-kB active site residues. Although there was an interaction between the ligand (drug) molecule and residues of NF-kB (chain C) and IkB (chain E) in the first 50 ns, the interaction between the drug and IkB (chain E) disappeared after 50 ns. This loss of interaction strengthened the ligand-NFκB interaction.

Figure 4

X-ray diffraction-based crystal structure of the IkB-α/NF-κB complex with solvents (PDB ID: 1NFI) at resolution of 2.70 Å, showing various chains in colour formats representing different molecules employed in the current study. For example, chain C (shown as a green cartoon model) represents NF-κB -P65, chain D (shown in a cyan cartoon model) represents NF-κB -P50, and chain E (shown in a magenta cartoon model) represents IkBα. Fig. 4A. Structure of the complex formed after docking of the drug molecule with NF-κB. The highlighted region represents the binding pocket of the drug molecule in the NF-κB molecule.
The binding pocket is represented by the labelled residues (G209, D210, E211, D257, R253, R259, S269, E285, etc., of the NFκB molecule and I102, N182, Q183, H184, etc., of the IkBα molecule). Fig. 4B. Structure of the complex formed after protein-protein docking of the SARS-CoV-2 spike glycoprotein (closed state) (PDB ID: 6VXX, shown in orange colour at a resolution of 2.80 Å) with the NF-κB molecule. The highlighted region represents the binding pocket of the spike protein in the NF-κB molecule. The binding pocket is represented by the labelled residues (G209, D210, E211, D257, R253, R259, S269, E285, etc., of the NFκB molecule and N182, Q183, H184, etc., of the IkBα molecule). This information indicates that the drug molecule binds in the same pocket that the spike protein used to interact with NF-κB, possibly to activate its translocation to the nucleus. Fig. 4C. Structure of the complex formed after protein-protein docking of the SARS-CoV-2 spike glycoprotein (shown in orange colour) with the NF-κB molecule (already docked with the drug molecule). The highlighted region represents the binding pocket of the spike protein in the NF-κB molecule in the presence of the drug molecule. The drug molecule occupies the same binding pocket on NF-κB that is also used by the spike protein during docking interaction, thus inhibiting the spike protein from interacting with NF-κB at its designated site. In the interim, the spike protein interacts with NF-κB at a different site and hence may not be able to activate it. Currently, these assumptions need validating experimental proof, which is lacking because of the strict restraint on experimentation with live samples from active human COVID-19 cases.
Figure 5

A 3-D structural alignment of the NF-κB-drug complexes (represented in a red cartoon model) and spike-protein-NF-κB-drug complexes (represented in a green cartoon model), with the NF-κB molecule represented in an orange cartoon model. Fig. 5A. These alignments show the conformational changes imposed in the structure of the NF-κB molecule upon binding of the drug and spike protein. Fig. 5B. Sequence-based comparison of the interacting residues of the NF-κB molecule with the drug sulindac sodium (yellow coloured bar), IκB molecule (green coloured bar) and spike protein (red coloured bar).
Figure 6

Comparison of the residues of the spike protein, MAP kinase and pLC gamma interacting with the residues of the NF-κB molecule. The underlined residues are in common (black: common in the s protein and pLC gamma, red: common in the spike protein and MAP kinase, and blue: common in all three).
Figure 7

MM-GBSA energy based visualization of docked complex highlighting the docked complex of receptor and sulindac sodium are represented with colour highlights on the ligand atoms showing contributions towards binding affinity. Blue represents the receptor and adaptive colours on ligand from Red to Green showcasing higher negative values to least values, respectively. The yellow dashed line represents the hydrogen bond with the receptor.